Vasudha Pharma Chem Ltd said the U.S. Department of Justice has dropped all charges against it after finding no evidence of wrongdoing, with no outstanding criminal or civil liabilities remaining against the company.
The company said it has entered into a Non-Prosecution Agreement with the DOJ on April 16, 2025 and had strengthened its compliance programme and internal controls, with a commitment to further enhancements, says PR Newswire.
Accusations and dismissal
Vasudha Pharma is a Hyderabad-based manufacturer of API and pharmaceutical intermediates with multiple facilities in Telangana and Andhra Pradesh.
In March 2025, Vasudha Pharma and several executives were indicted for allegedly manufacturing and distributing fentanyl precursor chemicals. On March 26, 2026, Vasudha entered a non-prosecution agreement, leading to the dismissal of all allegations.
DOJ observations
The DOJ acknowledged that Vasudha Pharma had no prior criminal or regulatory history and credited the company for its cooperation during the investigation. The company maintained its innocence throughout the process for more than a year.
Vasudha Pharma, Executive Director M Ashok Srinivas Raju, said, “All of us at Vasudha welcome the resolution of this matter. We are a family of dedicated chemists, chemical engineers, and scientists, and every employee at this company is committed to the responsible and ethical creation of critical pharmaceutical products that help medical patients around the world.”
Management response
Vasudha Pharma, Executive Director Anand Mantena, said the company was pleased with the outcome and would continue operations as usual while serving customers.
Crowell & Moring New York City Office Managing Partner Glen McGorty said the DOJ’s decision to dismiss all charges reflects the company’s transparency and cooperation during the investigation.
Background
Vasudha Pharma manufacturing facilities are accredited by the USFDA and regulatory agencies in Europe, Japan and Brazil, and the company maintains a working relationship with India’s Central Bureau of Narcotics. It employs over 4,000 people. It serves customers in over 90 countries including multinational corporations and pharmaceutical companies in the the US, Europe, and Latam countries.